Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical data, product performance and pipeline progress in movement disorders, neuropsychiatry, endocrinology and metabolic disease. The company regularly issues updates on its flagship VMAT2 inhibitor INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, including head-to-head pharmacologic studies, long-term efficacy analyses and peer-reviewed publications.
NBIX news commonly features clinical trial readouts across its pipeline. Recent releases have covered Phase 3 and Phase 4 data for INGREZZA in tardive dyskinesia and Huntington’s disease chorea, a Phase 3 study of valbenazine in dyskinetic cerebral palsy, and Phase 2 results for investigational compounds such as NBI-1070770 in major depressive disorder. Investors and clinicians can also follow updates on late-stage programs including osavampator for major depressive disorder and direclidine for schizophrenia and bipolar mania, as well as next-generation VMAT2 inhibitors and CRF-based therapies for metabolic diseases like obesity.
Another major theme in Neurocrine Biosciences news is financial and corporate reporting. The company announces quarterly net product sales for INGREZZA and CRENESSITY, provides guidance ranges for research and development and selling, general and administrative expenses, and discusses its R&D strategy at events such as its annual R&D Day and healthcare investor conferences. Management presentations at large industry meetings, including the J.P. Morgan Healthcare Conference and other investor conferences, are also highlighted in press releases.
This NBIX news page aggregates these updates so readers can quickly review earnings announcements, clinical milestones, R&D strategy briefings, investor conference appearances and key scientific publications related to Neurocrine Biosciences. For anyone tracking developments in tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, neuropsychiatric disorders or emerging CRF-based metabolic therapies, the news stream provides a concise view of the company’s ongoing activities and disclosures.
Neurocrine Biosciences (NBIX) presented a systematic literature review at the 2025 ISPOR Annual Meeting, examining the relationship between glucocorticoid (GC) dosage and adverse clinical outcomes in congenital adrenal hyperplasia (CAH) patients. The study analyzed 105 publications, with 65% focusing on CAH patients.
Key findings revealed that 62% of publications found statistically significant associations between GC dose and clinical outcomes, with 98% of these indicating higher GC doses led to adverse effects, including decreased bone mineral density, increased insulin resistance, and higher body mass index. The most commonly reported outcomes were bone health (43%), cardiometabolic (41%), and height and growth (24%).
Neurocrine Biosciences (NASDAQ: NBIX) has launched "ConnectING with Carnie™," a multimedia awareness campaign featuring Grammy-nominated singer Carnie Wilson. The campaign focuses on tardive dyskinesia (TD), an involuntary movement disorder caused by antipsychotic medications. While Wilson doesn't have TD herself, she will serve as an advocate to reduce stigma and encourage patients to seek treatment.
The initiative aims to empower individuals with TD to discuss their symptoms openly and explore treatment options, including INGREZZA® (valbenazine) capsules. The campaign will feature video interviews and resources on ConnectingWithCarnie.com, sharing stories from TD patients, care partners, and healthcare professionals about their experiences with the condition and its treatment.
Neurocrine Biosciences has launched a Phase 3 registrational program to test NBI-1117568, an oral muscarinic M4 selective orthosteric agonist, for treating adults with schizophrenia. This advancement follows successful Phase 2 results from August 2024.
The Phase 3 trial will be a global, double-blind, placebo-controlled study involving approximately 280 adult patients with schizophrenia experiencing acute symptom exacerbation. The study's primary goal is to measure reduction in the Positive and Negative Syndrome Scale (PANSS), with a secondary focus on the Clinical Global Impression of Severity (CGI-S) scale.
Phase 2 results showed promising outcomes with the 20 mg daily dose, including:
- A significant PANSS score reduction of 7.5 points versus placebo
- An 18.2-point reduction from baseline
- Improvements in secondary endpoints
- Good safety profile with minimal side effects
Neurocrine Biosciences (NBIX) has published a groundbreaking post-hoc analysis in The Journal of Clinical Psychiatry, demonstrating INGREZZA's long-term efficacy and safety in treating tardive dyskinesia (TD) in adults aged 65 and older.
The analysis, pooling data from two 48-week studies (KINECT 3 extension and KINECT 4), included 304 participants, with 55 (18.1%) aged ≥65 years. Key findings show that older adults achieved substantial TD symptom improvements within 8 weeks, sustained through 48 weeks:
- 95% of patients on INGREZZA 80mg showed ≥30% improvement in AIMS scores
- 95% on 80mg demonstrated CGI-TD improvements
- 90% on 80mg reported PGIC improvements
The safety profile remained consistent with no new treatment-emergent adverse events of clinical concern compared to younger adults. Common side effects included urinary tract infection and somnolence, each affecting 6 of 55 older participants.
Neurocrine Biosciences (NBIX) has scheduled its first quarter 2025 financial results conference call and webcast for May 5, 2025, at 1:30 p.m. Pacific Time. The company will release its Q1 2025 financial results via press release at 1:00 p.m. PT on the same day.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various conditions including tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company maintains a pipeline of compounds in mid- to late-phase clinical development across its core therapeutic areas.
Neurocrine Biosciences (NBIX) has appointed Dr. Sanjay Keswani as Chief Medical Officer (CMO), effective June 2, 2025. Dr. Keswani, bringing over 20 years of pharmaceutical industry experience, will lead clinical development and medical affairs activities.
Dr. Keswani succeeds Dr. Eiry W. Roberts, who served as CMO for seven years and will transition to a strategic advisory role. His previous positions include CEO of ImmunoBrain, SVP and R&D Head at Hoffman La Roche, and VP at Bristol-Myers Squibb.
During her tenure, Dr. Roberts led key developments including INGREZZA indication expansion and the crinecerfont program resulting in FDA approval of CRENESSITY. She also oversaw successful Phase 2 studies for osavampator and NBI-1117568, both advancing to registrational programs this year.